Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.
AuthorsCaswell, R J
Khoo, S H
Taylor, G P
Lambert, J S
AffiliationDepartment of GU Medicine and Teaching Primary Care Trust, Coventry PCT, Coventry.
Pregnancy Complications, Infectious
MetadataShow full item record
CitationUtility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. 2011, 22 (1):11-4 Int J STD AIDS
JournalInternational journal of STD & AIDS
AbstractThe pharmacokinetics of antiretroviral drugs in pregnancy is poorly understood. We reviewed the use of therapeutic drug monitoring (TDM) in clinical settings to document plasma concentrations of lopinavir during pregnancy and investigated how clinicians acted upon TDM results. A retrospective review was carried out of all HIV-infected pregnant women taking boosted lopinavir-based highly active antiretroviral therapy (HAART) at five National Health Service (NHS) centres in the UK between May 2004 and March 2007. Seventy-three women in receipt of lopinavir were identified, of whom 89% had plasma lopinavir concentrations above the suggested minimum recommended for wild-type HIV. Initial TDM results prompted dosage change in 10% and assessment of adherence and/or pharmacist review in 11%. TDM was repeated in 29%. TDM can play an important role in the clinical management of HIV-positive pregnant women, allowing informed dose modification and an alternative measure of adherence.
- Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
- Authors: Lambert JS, Else LJ, Jackson V, Breiden J, Gibbons S, Dickinson L, Back DJ, Brennan M, Connor EO, Boyle N, Fleming C, Coulter-Smith S, Khoo SH
- Issue date: 2011 Mar
- Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.
- Authors: Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, Stocker V, Lederman MM, Flexner C, AIDS Clinical Trials Protocol 5015 Team.
- Issue date: 2010 Jun
- Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
- Authors: Rosso R, Di Biagio A, Dentone C, Gattinara GC, Martino AM, Viganò A, Merlo M, Giaquinto C, Rampon O, Bassetti M, Gatti G, Viscoli C
- Issue date: 2006 Jun
- Antiretroviral therapies in women after single-dose nevirapine exposure.
- Authors: Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS, OCTANE A5208 Study Team.
- Issue date: 2010 Oct 14
- Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.
- Authors: Cressey TR, Urien S, Capparelli EV, Best BM, Buranabanjasatean S, Limtrakul A, Rawangban B, Sabsanong P, Treluyer JM, Jourdain G, Stek A, Lallemant M, Mirochnick M
- Issue date: 2015 Jan